Marc Beer is the CEO of Renovia. He has worked for over twenty years in the commercialization and developments in the fields of pharmaceuticals, biotechnology, diagnostics, and devices as well. He founded Renovia with two people, Yolanda Lorie, and Ramon Iglesias. Part of their successful business ventures includes financing with some of the global leading healthcare venture firms.
Prior to joining Renovia, Mr. Beer obtained a lot of experience in the field of healthcare that includes being the CEO of another pharmaceutical company. The goal of Renovia is to create and develop new and original treatment therapies for all of their clients around the globe. Their main focus is to help people that have rare and debilitating diseases.
Mr. Beer has held other positions before he came to work at Renovia. He was the CEO of Viatech in 2010-2017. This company was also a biotech company that specialized in the preservation, collection, and development of umbilical cords blood stem cell. While he was the CEO of Viatech, he served as an active member of the board of directors of Erynteck Pharma. Prior to coming to work for Viacell, Mr. Beer also worked in a lot of different roles for the company Genzyme. His last and most important job in that company was vice president of global marketing.
Mark Beer also served in marketing and sales roles at Abbott Laboratories. He was also a member of the Mass Life Science Board of the Massachusetts Commonwealth. Another role that he had was chairman of the board of Good Start Genetics as well as serving on their compensation committee. He graduated from the University of Miami where he got a Bachelor of Science degree.
The company that Mr. Beer is the present CEO of, Renovia is a company that is dedicated to delivering and discovering first line digital therapy and digital devices for women that have pelvic floor disorders such as urinary incontinence. In August of this year, they shared that they obtained $42.3 million in financing that includes $32.3 million in Series B equity and $10 million in venture debt. The money that was obtained will be used to pay for Renovia’s clinical trials, product development pipeline, corporate development, and their future commercial plans.
The Series B financing was led by Perceptive Advisors and Ascension Ventures, with many other companies participating as well. BayCross Capital Group helped Renovia with guidance in this project as well.
Renovia was created to commercialize and develop products for improving the first-line diagnoses and treatment to improve the condition-specific quality of life for women that have pelvic floor disorders. Their technologies make it possible for treatment via precise visualization of pelvic movement in a real-time when they train their pelvic muscles to get stronger while they watch the usage and improvement over a period of time. As a women’s health organization Renovia is searching for scalable and affordable care for pelvic floor disorders through the power of digital health. Renovia is a company that wants to help women with problems like urinary incontinence that can seriously affect them living a regular life. They strive to help woman work towards good health at a price that they can afford. Learn more: https://renoviainc.com/leadership/